Comparative Pharmacology
Head-to-head clinical analysis: DURLAZA versus TICLID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURLAZA versus TICLID.
DURLAZA vs TICLID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Durlaza (aspirin) irreversibly acetylates cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), inhibiting thromboxane A2 synthesis and reducing platelet aggregation.
Ticlopidine is a thienopyridine ADP receptor antagonist that irreversibly inhibits the P2Y12 receptor on platelets, preventing ADP-induced platelet aggregation.
325 mg orally once daily
250 mg orally twice daily
None Documented
None Documented
2-4 hours (prolonged in renal impairment; up to 10-20 hours in severe impairment). Clinical dosing adjustments required when CrCl <30 mL/min.
Terminal elimination half-life is approximately 30-50 hours (mean ~33 hours), with clinical effects lasting 7-10 days after discontinuation due to irreversible platelet binding.
Primarily renal (70-80% as unchanged drug), with 10-15% biliary/fecal. Negligible hepatic metabolism.
Primarily hepatic metabolism; 60% renal as metabolites, 23% fecal. Minimal parent drug excreted unchanged.
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent